PTEN and metastatic malignant neoplasm in the lymph nodes: To establish the efficacy of the small molecule inhibitors, two PTEN-positive cell lines, BPH1 (benign) and P4E6 (localised cancer) and two PTEN-negative cell lines LNCaP (lymph node metastasis) and PC3 (bone metastasis) were treated with a range of concentrations (0.01 – 30 μM) of AZD7328 or KU-0063794, for up to 48 hours.